📑 Scientific Program & Focus Areas: World Congress of Endocrinology

🧬 Diabetes, Inborn Errors of Metabolism & Technology

1. Next-Generation Continuous Glucose Monitoring (CGM) & Closed-Loop Systems

• Focus: Clinical outcomes of fully automated dual-hormone (insulin/glucagon) closed-loop systems, AI-driven predictive hypoglycemia algorithms, and non-invasive glycemic monitoring in type 1 and type 2 diabetes.

2. Disease-Modifying Immunotherapies in Type 1 Diabetes

• Focus: Delaying onset and preserving residual beta-cell function using monoclonal antibodies (e.g., anti-CD3 therapies), regulatory T-cell (Treg) induction, and autologous stem cell transplantation.

3. Dual and Triple Incretin Receptor Agonism in Type 2 Diabetes

• Focus: Mechanisms, long-term safety, and cardiometabolic advantages of GLP-1/GIP/Glucagon multi-receptor agonists, alongside protocols for preventing lean mass loss during rapid metabolic optimization.

4. Rare Inborn Errors of Carbohydrate and Lipid Metabolism

• Focus: Diagnostic genomic pipelines and targeted enzyme replacement therapies (ERT) for glycogen storage diseases, lipodystrophies, severe familial hypercholesterolemia, and lysosomal storage disorders.

5. Cellular Replacement Therapies & Encapsulated Islet Transplantation

• Focus: Stem-cell-derived functional beta-cell therapies, immune-evasive biomaterial encapsulation, and gene-edited allogeneic cell lines to eliminate systemic immunosuppression.

🦋 Thyroid, Parathyroid & Bone/Mineral Disorders

6. Molecular Oncology & Precision Therapeutics for Refractory Thyroid Cancer

• Focus: Genomic profiling of BRAF, RET, and NTRK alterations, redifferentiation strategies for radioiodine-refractory thyroid carcinoma, and novel multikinase inhibitors in medullary and anaplastic cancers.

7. Non-Surgical & Minimally Invasive Approaches to Thyroid Nodule Management

• Focus: Thermal ablation (radiofrequency, microwave, and laser) and high-intensity focused ultrasound (HIFU) for benign symptomatic nodules and low-risk microcarcinomas to reduce surgical morbidity.

8. Targeted Biologicals for Thyroid Eye Disease (TED) & Autoimmune Thyroiditis

• Focus: Insulin-like growth factor-1 receptor (IGF-1R) antagonists, IL-6 inhibitors, and FcRn blockers in moderate-to-severe, active Graves' orbitopathy and refractory Hashimoto's encephalopathy.

9. Advanced Therapies for Hypoparathyroidism & Mineral Homeostasis

• Focus: Long-acting recombinant human parathyroid hormone (rhPTH) analogs, calcimimetics, and targeted management of rare FGF23-mediated hypophosphatemic disorders.

10. Bone Microarchitecture, Anabolic Agents & Complex Osteoporosis

• Focus: Sequential and combination therapy regimens utilizing dual-acting bone-forming agents (e.g., sclerostin inhibitors) and antiresorptive agents in glucocorticoid-induced and high-fracture-risk osteoporosis.

🧠 Neuroendocrinology, Pituitary & Adrenal Axis

11. Molecular Subtyping & Surgical Innovations in Pituitary Adenomas/Neuroendocrine Tumors

• Focus: High-resolution intraoperative MRI, endoscopic transsphenoidal refinements, and molecular marker-guided management of aggressive corticotroph and somatotroph pituitary neuroendocrine tumors (PitNETs).

12. Adrenal Insufficiency & Chronotherapeutic Hormone Replacement

• Focus: Modified-release hydrocortisone formulations mimicking physiological circadian rhythms, subcutaneous hydrocortisone pumps, and novel biomarker monitoring for congenital adrenal hyperplasia (CAH).

13. Primary Aldosteronism & Complex Endocrine Hypertension

• Focus: Subtyping with functional imaging ($^{11}\text{C}$-metomidate PET-CT) vs. adrenal vein sampling, targeting somatic mutations (KCNJ5, CACNA1D), and selective mineralocorticoid receptor antagonists.

14. Pheochromocytoma and Paraganglioma (PPGL): Genomics to Theranostics

• Focus: Hereditary susceptibility gene panels (SDHx, VHL, MAX), hypoxia pathway signaling, and peptide receptor radionuclide therapy (PRRT with $^{177}\text{Lu}$-DOTATATE) for metastatic disease.

🌺 Reproductive, Gender & Developmental Endocrinology

15. Polycystic Ovary Syndrome (PCOS): Metabolic Subtyping and Lifespan Management

• Focus: Unraveling neuroendocrine pathophysiology (LH pulsatility, anti-Müllerian hormone elevation), insulin-sensitizing regimes, and cardio-metabolic risk mitigation from adolescence to menopause.

16. Gender-Affirming Endocrine Care & Long-Term Cardiometabolic Safety

• Focus: Evidence-based cross-sex hormone therapy protocols, personalized gonadotropin suppression, preserving fertility, and monitoring long-term bone density and cardiovascular safety profiles.

17. Hypogonadism & Androgen Replacement Paradigms

• Focus: Long-acting subcutaneous/selective androgen receptor modulators (SARMs), fertility preservation protocols in hypogonadotropic hypogonadism, and clinical risks surrounding late-onset male hypogonadism.

18. Pediatric Growth Disorders & Long-Acting Growth Hormone (LAGH) Analogs

• Focus: Clinical utility, compliance patterns, and safety surveillance of weekly growth hormone formulations in growth hormone deficiency (GHD), SGA, and rare genetic short stature syndromes.

⚖️ Obesity, Cardiometabolic Medicine & Adipose Biology

19. Adipose Tissue Dysfunction & Senescence in Metabolic Disease

• Focus: White-to-brown/beige adipocyte browning strategies, adipokine signaling pathways, and senolytic therapies targeting inflammation in visceral adiposity.

20. Endocrine Drivers of Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD/MASH)

• Focus: Pathophysiological crosstalk between insulin resistance, thyroid hormone receptor-beta (THR-$\beta$) agonists, and targeted pharmacological reversing of hepatic steatosis and fibrosis.

21. Pharmacological and Endoscopic Interventions in Bariatric Endocrinology

• Focus: Comparing multi-receptor anti-obesity medications with metabolic surgery and endoscopic sleeve gastroplasty, emphasizing weight regain mechanisms and gut hormone adaptation.

🌐 Cross-Cutting & Special Tracks

22. Endocrine Disrupting Chemicals (EDCs) & Environmental Health

• Focus: Epigenetic impacts of xenobiotic chemicals (bisphenols, PFAS, phthalates) on thyroid function, reproductive capacity, and transgenerational obesity risks.

23. Neuroendocrine Control of Appetite, Energy Expenditure & Metabolism

• Focus: Hypothalamic circuit mapping, agouti-related protein (AgRP)/pro-opiomelanocortin (POMC) neuronal regulation, and central nervous system signaling pathways in energy homeostasis.

24. Psychoneuroendocrinology and Endocrine-Driven Mood Disorders

• Focus: The neurosteroid axis, postpartum depression therapeutics (e.g., GABA-A receptor positive modulators), glucocorticoid dynamics in major depressive disorder, and endocrine-related cognitive decline.

25. Global Health Disparities, Climate Change & Tele-Endocrinology

• Focus: Managing diabetes and acute endocrine emergencies during natural disasters, addressing global insulin access inequality, and expanding remote continuous monitoring platforms in under-resourced regions.